ArticleMolecular therapy : the journal of the American Society of Gene Therapy2009
Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Association between the PSCA rs2976392 polymorphism and susceptibility to gastric cancer: a meta-analysis.Frontiers in genetics · 2025Pooled it
- Significance of PSCA as a novel prognostic marker and therapeutic target for cancer.Cancer cell international · 2024Review
- Electroporation-Based Treatments in Urology.Cancers · 2020Review
- Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.Oncotarget · 2017Article
- Article
- Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2016Article
- Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models.BMC cancer · 2016Article
- Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.Cancer immunology, immunotherapy : CII · 2016Article
- Local bacteria affect the efficacy of chemotherapeutic drugs.Scientific reports · 2015Article
- The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer.European journal of medical research · 2013Article
- Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments.Chinese clinical oncology · 2013Article
- Bacterial vectors for imaging and cancer gene therapy: a review.Cancer gene therapy · 2012Review
- DNA Vaccines for Prostate Cancer.Current cancer therapy reviews · 2012Article
- DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?Genetic vaccines and therapy · 2012Article
- An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.PloS one · 2012Article
- Engineered T cells for pancreatic cancer treatment.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2011Article
- Prostate stem cell antigen: a Jekyll and Hyde molecule?Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Review
- Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.Gene therapy · 2010Article
- Optimised electroporation mediated DNA vaccination for treatment of prostate cancer.Genetic vaccines and therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate stem cell antigen (PSCA) is a cell surface antigen expressed in normal human prostate and over expressed in prostate cancer. Elevated levels of PSCA protein in prostate cancer correlate with increased tumor stage/grade, with androgen independence and have higher expression in bone metastases. In this study, the PSCA gene was isolated from the transgenic adenocarcinoma mouse prostate cell line (TRAMPC1), and a vaccine plasmid construct was generated. This plasmid PSCA (pmPSCA) was delivered by intramuscular electroporation (EP) and induced effective antitumor immune responses against subcutaneous TRAMPC1 tumors in male C57 BL/6 mice. The pmPSCA vaccination inhibited tumor growth, resulting in cure or prolongation in survival. Similarly, the vaccine inhibited metastases in PSCA expressing B16 F10 tumors. There was activation of Th-1 type immunity against PSCA, indicating the breaking of tolerance to a self-antigen. This immunity was tumor specific and was transferable by adoptive transfer of splenocytes. The mice remained healthy and there was no evidence of collateral autoimmune responses in normal tissues. EP-assisted delivery of the pmPSCA evoked strong specific responses and could, in neoadjuvant or adjuvant settings, provide a safe and effective immune control of prostate cancer, given that there is significant homology between human and mouse PSCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.